NASDAQ:LOGCLogicBio Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LogicBio Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.03 0.00 (0.00 %) (As of 07/7/2020 12:48 PM ET) Add Compare Share Today's Range$8.00Now: $8.03▼$8.1850-Day Range$6.08MA: $7.50▼$8.7752-Week Range$3.05Now: $8.03▼$14.00Volume3,777 shsAverage Volume65,805 shsMarket Capitalization$188.14 millionP/E RatioN/ADividend YieldN/ABeta1.65 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingLogicBio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, LogicBio Therapeutics has a potential upside of 149.1% from its current price of $8.03.Amount of Analyst CoverageLogicBio Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesLogicBio Therapeutics has received 71 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLogicBio Therapeutics has received 81 “underperform” votes. (Add your “underperform” vote.)Community SentimentLogicBio Therapeutics has received 53.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about LogicBio Therapeutics and other stocks. Vote “Outperform” if you believe LOGC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LOGC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 23.40% of the stock of LogicBio Therapeutics is held by insiders.Percentage Held by Institutions47.91% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LogicBio Therapeutics are expected to grow in the coming year, from ($1.91) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LOGC Previous Symbol CUSIPN/A CIKN/A Webwww.logicbio.com Phone617-245-0399Debt Debt-to-Equity Ratio0.29 Current Ratio8.95 Quick Ratio8.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book4.36Profitability EPS (Most Recent Fiscal Year)($1.78) Net Income$-40,130,000.00 Net MarginsN/A Return on Equity-86.99% Return on Assets-69.95%Miscellaneous Employees23 Outstanding Shares23,430,000Market Cap$188.14 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:LOGC Rates by TradingView Receive LOGC News and Ratings via Email Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions How has LogicBio Therapeutics' stock been impacted by COVID-19 (Coronavirus)? LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LOGC shares have increased by 14.1% and is now trading at $8.03. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for LogicBio Therapeutics. When is LogicBio Therapeutics' next earnings date? LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for LogicBio Therapeutics. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics Inc (NASDAQ:LOGC) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.07. The company earned $1.02 million during the quarter. View LogicBio Therapeutics' earnings history. What price target have analysts set for LOGC? 2 equities research analysts have issued 12 month price objectives for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate LogicBio Therapeutics' share price to reach $20.00 in the next year. This suggests a possible upside of 149.1% from the stock's current price. View analysts' price targets for LogicBio Therapeutics. What are Wall Street analysts saying about LogicBio Therapeutics stock? Here are some recent quotes from research analysts about LogicBio Therapeutics stock: 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (6/26/2020) 2. Chardan Capital analysts commented, "We see limited read-across on nuclease-free editing controversy On 21 July, researchers from the California posted a manuscript to the bioRxiv preprint server outlining outlining unsuccessful efforts to reproduce efficient nuclease-free genome editing with clade F AAV vectors, based on a 2018 publication from Homology Medicines (unrated), which reported >50% editing with similar AAV vectors isolated from hematopoietic stem cells (AAVHSCs). Increasing attention drawn to the preprint to us may have sent Homology’s share price down >20% by the market close on July 25th. Below, we highlight some considerations for interpreting the data and the extent of potential read-across for other companies in the space." (7/29/2019) Has LogicBio Therapeutics been receiving favorable news coverage? Media stories about LOGC stock have been trending negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. LogicBio Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about LogicBio Therapeutics. Are investors shorting LogicBio Therapeutics? LogicBio Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 66,100 shares, a decline of 68.6% from the May 31st total of 210,200 shares. Based on an average daily volume of 60,500 shares, the short-interest ratio is presently 1.1 days. Currently, 0.5% of the shares of the company are short sold. View LogicBio Therapeutics' Current Options Chain. Who are some of LogicBio Therapeutics' key competitors? Some companies that are related to LogicBio Therapeutics include Vericel (VCEL), Agenus (AGEN), Osiris Therapeutics (OSIR), Aerie Pharmaceuticals (AERI), Avrobio (AVRO), AVITA MED LTD/S (RCEL), Proteon Therapeutics (PRTO), Autolus Therapeutics (AUTL), Oyster Point Pharma (OYST), Orchard Therapeutics (ORTX), Aptose Biosciences (APTO), Vaxart (VXRT), Prevail Therapeutics (PRVL), Scholar Rock (SRRK) and Rubius Therapeutics (RUBY). View all competitors. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Acceleron Pharma (XLRN), Alector (ALEC), Gossamer Bio (GOSS), Crispr Therapeutics (CRSP), Kaleido Biosciences (KLDO), Stoke Therapeutics (STOK), Tcr2 Therapeutics (TCRR), AbbVie (ABBV) and Akero Therapeutics (AKRO). Who are LogicBio Therapeutics' key executives? LogicBio Therapeutics' management team includes the following people: Mr. Frederic Chereau, Pres, CEO & Director (Age 52)Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)Mr. Tom Wilton, Chief Bus. Officer (Age 45)Dr. Leszek Lisowski Ph.D., Co-FounderDr. Adi Barzel, Co-Founder When did LogicBio Therapeutics IPO? (LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager. What is LogicBio Therapeutics' stock symbol? LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC." How do I buy shares of LogicBio Therapeutics? Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is LogicBio Therapeutics' stock price today? One share of LOGC stock can currently be purchased for approximately $8.03. How big of a company is LogicBio Therapeutics? LogicBio Therapeutics has a market capitalization of $188.14 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe. What is LogicBio Therapeutics' official website? The official website for LogicBio Therapeutics is www.logicbio.com. How can I contact LogicBio Therapeutics? LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
